Evommune (NYSE:EVMN) Upgraded at UBS Group

UBS Group upgraded shares of Evommune (NYSE:EVMN) to a hold rating in a report released on Sunday,Zacks reports.

Several other research firms have also recently commented on EVMN. Needham & Company LLC assumed coverage on Evommune in a research note on Wednesday, August 26th. They set a “buy” rating and a $28.00 target price for the company. Leerink Partners dropped their price objective on shares of Evommune from $28.00 to $22.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 9th. HC Wainwright reiterated a “neutral” rating on shares of Evommune in a report on Wednesday, September 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evommune in a research note on Friday, September 18th. Finally, Raymond James Financial set a $18.00 price objective on Evommune in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Evommune presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.80.

Evommune Price Performance

Shares of EVMN stock opened at $5.87 on Friday. The firm has a market cap of $212.85 million and a PE ratio of -0.53. The company has a 50-day moving average of $10.93 and a two-hundred day moving average of $16.89. Evommune has a 1-year low of $5.85 and a 1-year high of $33.20.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, August 6th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.21). Sell-side analysts anticipate that Evommune will post -3.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Evommune

A number of hedge funds and other institutional investors have recently bought and sold shares of EVMN. Janus Henderson Group PLC acquired a new stake in shares of Evommune in the first quarter valued at about $20,615,000. Defilade Capital Management L.P. raised its position in Evommune by 215.0% during the first quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock worth $15,601,000 after acquiring an additional 463,171 shares during the last quarter. Velan Capital Investment Management LP lifted its holdings in shares of Evommune by 1.1% in the second quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company’s stock valued at $5,997,000 after purchasing an additional 5,000 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Evommune in the first quarter valued at about $10,308,000. Finally, Stempoint Capital LP grew its position in shares of Evommune by 184.1% in the first quarter. Stempoint Capital LP now owns 193,777 shares of the company’s stock valued at $4,385,000 after purchasing an additional 125,581 shares during the last quarter.

About Evommune

Evommune, Inc is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company’s research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms.

Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders.